UNSPSC 51385809: Piroxicam pivalic ester

This classification denotes a cyclooxygenase inhibitor and aromatic compound with the molecular formula C20H21N3O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 39R048W55L, chemically known as propanoic acid, 2,2-dimethyl-, 2-methyl-1,1-dioxido-3-((2-pyridinylamino)carbonyl)-2h-1,2-benzothiazin-4-yl ester, but more generally known as piroxicam pivalic ester, which bears US NIH Compound Identifier 135836.

European Medicines Agency schedules piroxicam pivalic ester or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09936MIG. Most nations, for tariff purposes, schedule piroxicam pivalic ester under HS 29349990. SMILES: CC(C)(C)C(=O)OC1=C(N(S(=O)(=O)C2C1CCCC2)C)C(=O)NC3CCCCN3.

UNSPSC 51385809 Piroxicam pivalic ester is a Commodity code that does not align with the state and local procurement activity tagged under it. The three recent opportunities posted under this code involve naloxone procurement, direct-to-manufacturer pharmacy programs, and generic multi-source pharmaceutical contracting—none of which involve piroxicam pivalic ester, a nonsteroidal anti-inflammatory drug. The mismatch suggests either a classification error in the source data or use of this code as a catch-all category for pharmaceutical procurement that falls outside its nominal scope.

The recent activity shows state and local governments buying naloxone for emergency response and drug-deactivation systems, generic pharmaceuticals through cooperative purchasing agreements, and exploring direct manufacturer relationships for prescription fulfillment. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances spanning multiple states (Minnesota Multistate Cooperative Purchasing Alliance, serving Minnesota and Oregon). Representative solicitations include Seminole County's IFB 60459723LAS for 1,900 units of naloxone and 800 safe drug-deactivation systems annually (response deadline July 26, 2023); Texas HHS Commission's RFI HHS0017013 on therapeutic pharmacy initiative direct-to-manufacturer prescriptions (posted April 3, 2026); and MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products (due March 26, 2026, with awards effective July 1, 2026). Geographic activity concentrates in Florida, Texas, and the upper Midwest (Minnesota and Oregon). The code shows little relevant recent activity under its stated pharmaceutical specialty; readers pursuing state and local pharmaceutical supply contracts should verify the correct code assignment with the issuing jurisdiction before submitting responses.